Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HS-10382 monotherapy in newly diagnosed chronic phase CML
ChiCTR2400088230Phase 2Recruiting
- Sponsor
- Ruijin Hospital
- Start
- Aug 2024
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label, single-arm trial of TERN-701 in chronic myelogenous leukemia (CML), sponsored by Ruijin Hospital. Primary endpoint: Major molecular response rate at 24 weeks. Started Aug 2024; status: recruiting.
02
Drugs
TERN-701
03
Conditions
chronic myelogenous leukemia (CML)
Beyond the preview
Go deeper on ChiCTR2400088230.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2400088230.